Number O
of O
glucocorticoid B-protein
receptors I-protein
in O
lymphocytes I-cell_type
and O
their O
sensitivity O
to O
hormone I-protein
action O
. O
The O
study O
demonstrated O
a O
decreased O
level O
of O
glucocorticoid B-protein
receptors I-protein
( O
GR B-protein
) O
in O
peripheral B-cell_type
blood I-cell_type
lymphocytes I-cell_type
from O
hypercholesterolemic O
subjects O
, O
and O
an O
elevated O
level O
in O
patients O
with O
acute O
myocardial O
infarction O
. O
In O
the O
lymphocytes I-cell_type
with O
a O
high O
GR B-protein
number O
, O
dexamethasone O
inhibited O
[ O
3H O
] O
-thymidine O
and O
[ O
3H O
] O
-acetate O
incorporation O
into O
DNA O
and O
cholesterol O
, O
respectively O
, O
in O
the O
same O
manner O
as O
in O
the O
control O
cells I-cell_line
. O
On O
the O
other O
hand O
, O
a O
decreased O
GR B-protein
number O
resulted O
in O
a O
less O
efficient O
dexamethasone O
inhibition O
of O
the O
incorporation O
of O
labeled O
compounds O
. O
These O
data O
showed O
that O
the O
sensitivity O
of O
lymphocytes I-cell_type
to O
glucocorticoids O
changed O
only O
with O
a O
decrease O
of O
GR B-protein
level O
. O
[ O
1 I-protein
, O
25-Dihydroxyvitamin O
D3 O
receptors I-protein
in O
lymphocytes I-cell_type
and O
T- O
and O
B-lymphocyte B-protein
count O
in O
patients O
with O
glomerulonephritis O
] O
Content O
of O
receptors O
to O
hormonal O
form O
of O
vitamin O
D3 O
, O
1.25 I-protein
( O
OH O
) O
2D3 I-cell_line
, O
constituted O
27.3 O
fmole/mg O
of O
protein B-protein
in O
lymphocytes I-cell_type
of O
peripheric O
blood O
of O
children O
with O
glomerulonephritis O
. O
In O
the O
patients O
concentration O
of O
total O
and O
ionized O
form O
of O
Ca2+ O
was O
decreased O
down O
to O
2.04 O
mmole/L O
and O
1.09 O
mmole/L O
, O
respectively O
, O
while O
an O
increase O
in O
parathormone O
( O
PTH O
) O
by O
36 I-protein
% O
and O
a O
distinct O
decrease O
in O
25 O
( O
OH O
) O
D O
concentration O
( O
lower O
than O
1.25 O
ng/ml O
) O
was O
found O
in O
blood O
; O
content O
of O
cAMP O
was O
also O
decreased O
in O
lymphocytes I-cell_type
by O
33 O
% O
. O
At O
the O
same O
time O
, O
total O
content O
of O
T B-cell_type
lymphocytes I-cell_type
was O
decreased O
1.5-fold O
in O
peripheric O
blood O
. O
Treatment O
with O
I-hydroxyvitamin B-protein
D3 O
( O
1-1.5 B-cell_type
mg O
daily O
, O
within O
4 O
weeks O
) O
led O
to O
normalization O
of O
total O
and O
ionized O
form O
of O
Ca2+ O
and O
of O
25 O
( O
OH O
) O
D O
, O
but O
did O
not O
affect O
the O
PTH O
content O
in O
blood O
. O
Concentration O
of O
the O
receptors O
to O
1.25 O
( O
OH O
) O
2D3 I-cell_line
was O
elevated O
up O
to O
39.7 O
fmole/mg O
after O
I I-protein
week O
of O
the O
treatment O
, O
whereas O
it O
was O
decreased O
to O
the O
initial O
level O
24.8 O
fmole/mg O
within O
4 O
weeks O
; O
simultaneous O
alteration O
in O
the O
cAMP O
content O
was O
observed O
in O
lymphocytes I-cell_type
. O
Treatment O
with O
1- O
( O
OH O
) O
D3 O
normalized O
also O
the O
T B-cell_type
lymphocytes I-cell_type
content O
in O
peripheric O
blood O
. O
The O
data O
obtained O
suggest O
that O
under O
conditions O
of O
glomerulonephritis O
only O
high O
content O
of O
receptors O
to O
1.25 O
( O
OH O
) O
2D3 I-cell_line
in O
lymphocytes I-cell_type
enabled O
to O
perform O
the O
cell O
response O
to O
the O
hormone I-protein
effect O
. O
Tumor O
and O
serum O
beta-2-microglobulin O
expression O
in O
women O
with O
breast O
cancer O
. O
To O
investigate O
whether O
the O
tumor O
expression O
of O
beta-2-microglobulin O
( O
beta I-protein
2-M O
) O
could O
serve O
as O
a O
marker O
of O
tumor B-cell_type
biologic O
behavior O
, O
the O
authors O
studied O
specimens O
of O
breast O
carcinomas O
from O
60 O
consecutive O
female O
patients O
. O
Presence O
of O
beta I-protein
2-M B-DNA
was O
analyzed O
by O
immunohistochemistry O
. O
No O
significant O
correlations O
were O
found O
between O
tumor B-protein
beta I-protein
2-M B-DNA
expression O
and O
several O
histologic O
attributes O
such O
as O
type O
, O
histologic O
and O
nuclear O
grades I-DNA
, O
mitotic O
index O
, O
necrosis O
, O
vascular B-protein
invasion O
, O
and O
lymphocytic I-cell_line
infiltration O
. O
Likewise O
, O
beta I-protein
2-M B-DNA
was O
not O
associated O
with O
markers O
of O
disease O
extension O
such O
as O
TNM O
, O
( O
UICC B-cell_type
, O
classification O
of O
malignant O
tumors O
) O
staging O
and O
axillary O
lymph O
node O
involvement O
or O
with O
estrogen O
, O
progesterone O
, O
and O
glucocorticoid B-protein
receptor I-protein
levels O
. O
However O
, O
there O
was O
a O
significantly O
positive O
association O
between O
tumor B-protein
beta I-protein
2-M B-DNA
expression O
and O
the O
degree O
of O
lymphocytic I-cell_line
infiltration O
in O
the O
tumor O
tissue I-cell_type
. O
Beta O
2-M B-DNA
serum B-DNA
levels O
were O
determined O
by O
an O
enzyme-linked O
immunosorbent O
assay O
in O
samples O
from O
22 O
of O
the O
above O
women O
. O
Although O
some O
of O
the O
highest O
values O
had O
been O
obtained O
in O
women O
with O
larger O
( O
T4 I-cell_line
) O
primary O
tumors O
, O
the O
authors O
failed O
to O
detect O
any O
statistical O
relationship O
between O
beta I-protein
2-M B-DNA
expression O
in O
the O
tumor O
with O
serum B-DNA
levels O
or O
between O
serum B-protein
beta I-protein
2-M B-DNA
and O
the O
above O
histologic O
, O
laboratory O
, O
and O
clinical B-protein
factors I-protein
. O
[ O
Preliminary O
observation O
of O
level O
free-form O
E I-DNA
receptor I-protein
levels O
in O
serum B-DNA
of O
normal O
childbearing-aged O
and O
pregnant O
women O
] O
In O
137 O
cases O
of O
childbearing-aged O
and O
pregnant O
women O
, O
free O
form O
E I-DNA
receptor I-protein
levels O
( O
sE O
) O
in O
serum B-DNA
were O
measured O
by O
ELISA O
. O
The O
level O
of O
sE O
was O
significantly O
decreased O
during O
the O
first O
trimester O
, O
slightly O
higher O
in O
the O
second O
trimester O
, O
and O
recovered O
to O
normal O
in O
the O
third O
trimester O
. O
The O
level O
remained O
lower O
in O
29 O
PIH O
women O
but O
appeared O
higher O
in O
overdue O
pregnancies O
as O
compared O
with O
the O
normal O
3rd O
trimester O
range O
. O
The O
results O
indicate O
that O
there O
is O
a O
relationship O
between O
a O
change O
in O
T O
cell O
function O
and O
pregnancy O
. O
Kappa O
B-specific B-protein
DNA O
binding I-protein
proteins I-protein
: O
role O
in O
the O
regulation O
of O
human B-protein
interleukin-2 I-DNA
gene I-DNA
expression O
. O
Transcriptional O
activation O
of O
the O
human B-protein
interleukin-2 I-protein
( O
IL-2 B-protein
) I-DNA
gene I-DNA
, O
like O
induction O
of O
the O
IL-2 B-DNA
receptor I-DNA
alpha I-protein
( I-DNA
IL-2R I-DNA
alpha I-protein
) I-DNA
gene I-DNA
and O
the O
type O
1 O
human O
immunodeficiency O
virus O
( O
HIV-1 O
) O
, O
is O
shown O
to O
be O
modulated O
by O
a O
kappa O
B-like I-DNA
enhancer B-DNA
element I-DNA
. O
Mutation O
of O
a O
kappa O
B I-protein
core B-DNA
sequence I-DNA
identified O
in O
the O
IL-2 B-DNA
promoter I-DNA
( O
-206 I-DNA
to O
-195 O
) O
partially O
inhibits O
both O
mitogen- O
and O
HTLV-I O
Tax-mediated O
activation O
of O
this O
transcription O
unit O
and O
blocks O
the O
specific O
binding O
of O
two O
inducible O
cellular B-protein
factors I-protein
. O
These O
kappa O
B-specific I-protein
proteins I-protein
( O
80 O
to O
90 O
and O
50 O
to O
55 O
kilodaltons O
) O
similarly O
interact O
with O
the O
functional O
kappa O
B I-DNA
enhancer I-DNA
present O
in O
the O
IL-2R B-DNA
alpha I-DNA
promoter I-DNA
. O
These O
data O
suggest O
that O
these O
kappa O
B-specific I-protein
proteins I-protein
have O
a O
role O
in O
the O
coordinate O
regulation O
of O
this O
growth O
factor-growth B-protein
factor I-protein
receptor I-protein
gene I-DNA
system O
that O
controls O
T O
cell O
proliferation O
. O
Novel B-protein
region I-DNA
within O
the O
V O
kappa B-DNA
gene I-DNA
promoter I-DNA
is O
responsible O
for O
tissue I-cell_type
and O
stage-specific O
expression O
of O
immunoglobulin O
genes O
in O
human O
lymphoid I-cell_type
neoplasms O
. O
Immunoglobulin O
gene-specific I-DNA
transacting B-protein
factors I-protein
have O
been O
shown O
to O
play O
a O
role O
in O
lymphoid O
tissue-specific O
expression O
of O
immunoglobulin O
genes O
. O
The O
role O
of O
these B-protein
factors I-protein
in O
B-cell O
differentiation O
and O
stage-specific O
expression O
of O
these O
genes I-DNA
is O
, O
however O
, O
not O
fully O
understood O
. O
We O
have O
used O
a O
model O
of O
human B-cell_line
lymphoid I-cell_type
neoplasia O
to O
address O
this O
question O
. O
Different O
fragments I-DNA
of O
unrearranged O
human O
variable I-protein
region O
of O
immunoglobulin B-protein
kappa O
gene O
( O
V B-protein
kappa O
) O
were O
used O
for O
cell-free O
in O
vitro O
transcription O
and O
DNA O
mobility O
shift O
assays O
. O
Previously O
described O
enhancement O
of O
in O
vitro O
transcription O
that O
was O
only O
seen O
with O
nuclear O
extracts O
derived O
from O
B-cell O
neoplasms O
corresponding O
to O
the O
late O
stages O
of O
B-cell O
differentiation O
was O
shown O
to O
be O
dependent O
on O
the O
actions O
of O
these O
factor I-protein
( O
s O
) O
on O
the O
DNA B-protein
region I-DNA
within O
the O
V O
kappa B-DNA
gene I-DNA
promoter I-DNA
. O
This O
region I-DNA
is O
located O
within O
the O
920 B-DNA
bp I-DNA
fragment I-DNA
located O
210 B-DNA
bp I-DNA
upstream I-DNA
from O
the O
coding I-DNA
region I-DNA
and O
this O
fragment I-protein
represents O
a O
possible O
novel O
DNA B-protein
region I-DNA
, O
which O
plays O
a O
role O
in O
the O
stage- B-DNA
and O
tissue-specific O
expression O
of O
immunoglobulin O
genes O
. O
[ O
Determination O
of O
the O
sensitivity O
to O
glucocorticoids O
in O
vitro O
] O
A O
modified B-DNA
method O
for O
the O
determination O
of O
glucocorticoid B-protein
receptors I-protein
in O
human B-cell_type
lymphocytes I-cell_type
is O
suggested O
. O
The O
principal O
distinction O
of O
the O
method O
is O
standardization O
by O
the O
lymphocyte O
count O
in O
a O
sample O
( O
1 O
mln O
) O
and O
the O
labeled O
hormone I-protein
concentration O
. O
The O
modification O
saves O
time O
and O
money O
, O
limits O
the O
range O
of O
the O
data O
variations O
, O
and O
makes O
use O
of O
a O
lesser O
volume O
of O
blood O
. O
Examinations O
of O
70 B-protein
children O
aged O
4 O
to O
15 O
suffering O
from O
the O
nephrotic O
form O
of O
glomerulonephritis O
have O
made O
it O
possible O
to O
distinguish O
two O
groups O
of O
patients O
: O
with O
relatively O
high O
values O
of O
specific O
binding O
X B-DNA
= O
6820.1 O
+/- O
530.0 O
( O
n O
= O
30 O
, O
p O
= O
0.95 O
, O
t O
= O
2.04 O
) O
, O
this O
corresponding O
to O
a O
clinical O
form O
of O
hormone I-protein
-sensitive O
glomerulonephritis O
, O
and O
with O
relatively O
low O
values O
of O
specific O
binding O
X B-DNA
= O
1815.2 O
+/- O
302.8 O
( O
n O
= O
40 O
, O
p O
= O
0.95 O
, O
t O
= O
1.96 O
) O
, O
that O
corresponds O
to O
hormone I-protein
-resistant O
glomerulonephritis O
. O
Dynamic O
studies O
have O
not O
shown O
any O
statistically O
significant O
changes O
in O
the O
specific O
binding O
values O
. O
These O
results O
permit O
regarding O
the O
specific O
binding O
value O
as O
a O
prognostic O
criterion O
in O
the O
assessment O
of O
corticosteroid O
therapy O
; O
this O
allows O
a O
wide O
employment O
of O
the O
described O
method O
in O
practical O
nephrology O
. O
Octamer-binding B-protein
proteins I-protein
from O
B O
or O
HeLa B-cell_line
cells I-cell_line
stimulate O
transcription O
of O
the O
immunoglobulin O
heavy-chain B-DNA
promoter I-DNA
in O
vitro O
. O
The O
B-cell O
-type O
specificity O
of O
the O
immunoglobulin I-protein
( O
Ig O
) O
heavy-chain O
and O
light-chain B-DNA
promoters I-DNA
is O
mediated O
by O
an O
octanucleotide O
( O
OCTA O
) I-DNA
element I-DNA
, O
ATGCAAAT O
, O
that O
is O
also O
a O
functional O
component O
of O
other O
RNA I-RNA
polymerase O
II I-DNA
promoters I-DNA
, O
such O
as O
snRNA O
and O
histone I-protein
H2B B-DNA
promoters I-DNA
. O
Two O
nuclear B-protein
proteins I-protein
that O
bind O
specifically O
and O
with O
high O
affinity O
to O
the O
OCTA B-DNA
element I-DNA
have O
been O
identified O
. O
NF-A1 I-protein
is O
present O
in O
a O
variety O
of O
cell O
types I-cell_type
, O
whereas O
the O
presence O
of O
NF-A2 I-protein
is O
essentially O
confined O
to O
B B-cell_type
cells I-cell_type
, O
leading O
to O
the O
hypothesis O
that O
NF-A2 I-protein
activates O
cell-type-specific I-protein
transcription O
of O
the O
Ig O
promoter I-DNA
and O
NF-A1 I-protein
mediates O
the O
other O
responses O
of O
the O
OCTA B-DNA
element I-DNA
. O
Extracts O
of O
the O
B-cell O
line O
, O
BJA-B B-protein
, O
contain O
high O
levels O
of O
NF-A2 I-protein
and O
specifically O
transcribe O
Ig O
promoters I-DNA
. O
In O
contrast O
, O
extracts O
from O
HeLa B-cell_line
cells I-cell_line
transcribed O
the O
Ig O
promoter I-DNA
poorly O
. O
Surprisingly O
, O
addition O
of O
either O
affinity-enriched O
NF-A2 I-protein
or O
NF-A1 I-protein
to O
either O
a O
HeLa B-cell_line
extract O
or O
a O
partially O
purified O
reaction O
system O
specifically O
stimulates O
the O
Ig O
promoter I-DNA
. O
This O
suggests O
that O
the O
constitutive O
OCTA-binding I-protein
factor I-protein
NF-A1 I-protein
can O
activate O
transcription O
of O
the O
Ig O
promoter I-DNA
and O
that O
B-cell O
-specific O
transcription O
of O
this O
promoter I-DNA
, O
at O
least O
in O
vitro O
, O
is O
partially O
due O
to O
a O
quantitative O
difference O
in O
the O
amount O
of O
OCTA-binding B-protein
protein I-protein
. O
Because O
NF-A1 I-protein
can O
stimulate O
Ig O
transcription O
, O
the O
inability O
of O
this O
factor O
to O
activate O
in O
vivo O
the O
Ig O
promoter I-DNA
to O
the O
same O
degree O
as O
the O
snRNA B-DNA
promoters I-DNA
probably O
reflects O
a O
difference O
in O
the O
context O
of O
the O
OCTA B-DNA
element I-DNA
in O
these O
two O
types I-cell_type
of O
promoters B-DNA
. O
Identification O
of O
a O
putative B-protein
regulator I-protein
of O
early O
T O
cell O
activation I-DNA
genes I-DNA
. O
Molecules O
involved O
in O
the O
antigen I-protein
receptor-dependent I-protein
regulation O
of O
early O
T O
cell O
activation I-DNA
genes I-DNA
were O
investigated O
with O
the O
use O
of O
functional O
sequences O
of O
the O
T O
cell O
activation-specific I-DNA
enhancer I-DNA
of O
interleukin-2 B-protein
( O
IL-2 B-protein
) O
. O
One O
of O
these O
sequences O
forms O
a O
protein I-protein
complex I-protein
, O
NFAT-1 B-protein
, O
specifically O
with O
nuclear O
extracts O
of O
activated I-protein
T I-protein
cells I-cell_type
. O
This O
complex I-protein
appeared O
10 O
to O
25 O
minutes O
before O
the O
activation O
of O
the O
IL-2 B-DNA
gene I-DNA
. O
Studies O
with O
inhibitors O
of O
protein B-protein
synthesis O
indicated O
that O
the O
time O
of O
synthesis O
of O
the O
activator I-protein
of O
the O
IL-2 B-DNA
gene I-DNA
in O
Jurkat B-cell_line
T I-cell_line
cells I-cell_type
corresponds O
to O
the O
time O
of O
appearance O
of O
NFAT-1 B-protein
. O
NFAT-1 B-protein
, O
or O
a O
very O
similar O
protein I-protein
, O
bound O
functional I-DNA
sequences O
of O
the O
long I-DNA
terminal I-DNA
repeat I-DNA
( O
LTR B-DNA
) O
of O
the O
human O
immunodeficiency O
virus O
type O
1 O
; O
the O
LTR B-DNA
of O
this O
virus O
is O
known O
to O
be O
stimulated O
during O
early O
T O
cell O
activation O
. O
The O
binding I-DNA
site I-DNA
for O
this O
complex I-protein
activated I-protein
a O
linked B-DNA
promoter I-DNA
after O
transfection O
into O
antigen I-protein
receptor-activated I-protein
T B-cell_type
cells I-cell_type
but O
not O
other O
cell O
types I-cell_type
. O
These O
characteristics O
suggest O
that O
NFAT-1 B-protein
transmits O
signals O
initiated O
at O
the O
T O
cell I-protein
antigen I-protein
receptor I-protein
. O
Characterization O
of O
thyroid O
hormone I-protein
receptors I-protein
in O
human O
IM-9 I-cell_type
lymphocytes I-cell_type
. O
Although O
putatively O
identified O
more O
than O
10 O
years O
ago O
, O
thyroid O
hormone I-protein
receptors I-protein
in O
human O
tissues I-cell_type
remain O
poorly O
characterized O
. O
As O
a O
first O
step O
towards O
understanding O
the O
mechanism O
of O
thyroid O
hormone I-protein
action O
in O
man O
we O
have O
characterized O
T3 B-DNA
binding I-DNA
sites I-DNA
in O
nuclei O
of O
the O
human O
lymphoblastoid I-cell_line
line O
, O
IM-9 O
cells I-cell_line
. O
In O
whole O
cell O
experiments O
at O
37 O
degrees O
C I-protein
, O
nuclear O
binding I-DNA
of O
[ O
125I B-protein
] O
T3 I-protein
was O
saturable O
( O
Kd O
34 O
+/- O
6 O
pmol/l O
) O
and O
of O
finite O
capacity O
( O
approximately O
equal O
to O
350 O
sites/cell I-RNA
) O
. O
The O
binding I-DNA
sites I-DNA
were O
extracted O
from O
a O
nuclear O
pellet O
by O
treatment O
with O
0.4 O
mol/l O
KCl B-protein
and O
sonication O
. O
Separation O
of O
bound O
from O
free O
[ O
125I B-protein
] O
T3 I-protein
in O
the O
extracts O
was O
achieved O
using O
the O
calcium O
phosphate O
matrix O
, O
hydroxyapatite O
at O
a O
concentration O
of O
0.3 O
ml O
of O
a O
150 B-DNA
g/l O
slurry O
. O
Rectilinear O
Scatchard O
plots O
were O
obtained O
only O
when O
the O
hydroxyapatite O
was O
washed O
with O
a O
buffer O
containing O
0.5 O
% O
Triton O
X-100 O
. O
Under O
these O
conditions O
T3 B-DNA
binding I-DNA
sites I-DNA
in O
the O
nuclear O
extracts O
were O
present O
at O
a O
concentration O
of O
22.4 O
+/- O
8.6 O
fmol/mg I-protein
protein I-protein
and O
showed O
an O
affinity O
of O
( O
Kd O
, O
room O
temperature O
) O
140 O
+/- O
10 O
pmol/l O
. O
The O
same O
assay O
system O
was O
used O
to O
determine O
the O
hierarchy O
of O
affinities O
for O
a O
range O
of O
natural B-cell_line
and O
synthetic O
analogues O
. O
Calling O
T3 I-protein
100 O
, O
the O
order O
of O
potencies O
observed O
was O
: O
Triac O
, O
500 O
; O
3 O
, O
5-diiodo-3'-isopropylthyronine O
, O
89 O
; O
T4 O
, O
32 O
; O
3 O
, O
5-dimethyl-3'isopropylthyronine I-protein
2 I-protein
; O
3 O
, O
5-T2 B-protein
, O
0.7 O
, O
rT3 B-protein
, O
0.4 O
; O
3'5'-T2 O
, O
less O
than O
0.01 O
. O
These O
results O
suggest O
that O
the O
T3 B-DNA
binding I-DNA
sites I-DNA
present O
in O
human O
IM-9 O
lymphocyte O
nuclei O
and O
extracts O
thereof O
are O
thyroid O
hormone I-protein
receptors I-protein
. O
These O
cells I-cell_line
may O
be O
a O
useful O
tool O
to O
increase O
our O
understanding O
of O
human B-cell_line
T3 I-protein
receptors I-protein
Definition O
of O
T-cell O
specific O
DNA-binding B-protein
factors I-protein
that O
interact O
with O
a O
3'-silencer B-DNA
in O
the O
CD4+ B-cell_line
T-cell O
gene O
Rpt-1 B-protein
. O
Analysis O
of O
the O
region O
3 O
' O
to O
the O
CD4+ B-cell_line
T-cell O
gene O
Rpt-1 B-protein
( O
encoding O
regulatory I-protein
protein I-protein
T-lymphocyte I-protein
1 I-protein
) O
led O
to O
the O
definition O
of O
a O
silencer I-DNA
element I-DNA
that O
inhibits O
heterologous B-DNA
gene I-DNA
expression O
in O
certain O
CD4+ B-cell_line
T-cell B-cell_line
lines I-cell_line
but O
not O
in O
B-cell O
or O
non-lymphoid B-DNA
cell I-cell_line
lines I-cell_line
. O
Functional O
silencer O
activity O
in O
vivo O
was O
associated O
with O
the O
presence O
of O
a O
specific O
silencer-DNA-protein B-protein
complex I-protein
in O
electrophoretic O
mobility O
shift O
assays O
with O
T-cell O
extracts O
. O
Formation O
of O
this O
complex I-protein
was O
selectively O
inhibited O
by O
the O
region I-DNA
in O
HIV-1 O
containing O
a O
silencer I-DNA
element I-DNA
. O
We O
discuss O
the O
possibility O
that O
DNA-binding B-protein
factors I-protein
may O
coregulate O
HIV-1 O
and O
Rpt-1 B-protein
gene I-DNA
expression O
through O
a O
common B-protein
transcriptional O
silencer I-protein
element I-DNA
. O
Congenital O
immunodeficiencies O
associated O
with O
absence O
of O
HLA B-DNA
class B-DNA
II I-protein
antigens I-protein
on O
lymphocytes I-cell_type
result O
from O
distinct O
mutations O
in O
trans-acting O
factors I-protein
. O
Coordinate O
regulation O
of O
HLA B-DNA
class B-DNA
II I-DNA
gene I-DNA
expression O
during O
development O
and O
coinduction O
of O
class B-cell_line
II I-DNA
genes I-DNA
by O
soluble B-protein
factors I-protein
suggests O
that O
common O
trans-acting O
factor I-protein
( O
s O
) O
control O
expression O
of O
these O
genes I-DNA
. O
In O
B-lymphoblastoid B-protein
cell I-cell_line
lines I-cell_line
derived O
from O
two O
independent O
class B-DNA
II-deficient I-cell_line
bare O
lymphocyte O
syndrome O
patients O
, O
we O
observed O
a O
drastic O
decrease O
in O
transcription O
rates O
of O
the O
class B-DNA
II I-DNA
genes I-DNA
. O
When O
these O
cell I-cell_line
lines I-cell_line
are O
fused O
, O
class O
II I-DNA
genes I-DNA
are O
reexpressed O
, O
indicating O
that O
immunodeficiencies O
in O
bare O
lymphocyte O
syndrome O
patients O
are O
the O
result O
of O
two O
distinct O
mutations O
. O
Further O
studies O
show O
that O
genes I-DNA
governing O
the O
expression O
of O
class B-cell_line
II I-protein
antigens I-protein
fall O
into O
at O
least O
three O
complementation O
groups O
; O
two O
of O
these O
were O
previously O
unidentified O
in O
mutant B-cell_line
cell I-cell_line
lines I-cell_line
generated O
in O
vitro O
. O
In O
addition O
, O
we O
report O
the O
identification O
of O
two O
discrete O
complexes O
, O
NFX1.1 O
and O
NFX1.2 O
, O
that O
bind O
to O
the O
DRA B-DNA
X B-DNA
consensus B-DNA
element I-DNA
. O
Though O
the O
mutation O
in O
at O
least O
one O
mutant B-cell_line
line O
generated O
in O
vitro O
( O
RJ2.2.5 O
) O
affects O
products I-protein
functioning O
via O
interaction O
with O
the O
X B-DNA
box I-DNA
, O
clear O
alterations O
in O
either O
NFX1.1 O
or O
NFX1.2 O
are O
not O
found O
in O
any O
of O
the O
mutant B-cell_line
cell I-cell_line
lines I-cell_line
. O
In O
vivo O
responsiveness O
to O
glucocorticoid O
correlated O
with O
glucocorticoid B-protein
receptor I-protein
content O
in O
peripheral B-cell_type
blood I-cell_type
leukocytes I-cell_type
in O
normal O
humans O
. O
Dexamethasone O
loading O
tests O
( O
0.1 O
mg O
dexamethasone/kg O
, O
iv O
) O
were O
performed O
in O
18 I-protein
normal O
males O
to O
evaluate O
the O
individual O
responsiveness O
to O
glucocorticoid O
. O
There O
were O
inter-individual O
differences O
in O
increase O
in O
peripheral B-cell_type
blood O
polymorphonuclear O
leukocyte B-protein
count O
, O
decrease O
in O
peripheral B-cell_type
blood O
lymphocyte I-cell_line
count O
, O
and O
increase O
in O
plasma O
free O
fatty O
acids I-protein
levels O
after O
dexamethasone O
injection O
. O
In O
addition O
, O
there O
was O
a O
significant O
correlation O
between O
the O
maximum O
increase O
in O
polymorphonuclear B-cell_type
leukocytes B-cell_type
and O
the O
maximum O
decrease O
in O
lymphocytes I-cell_line
( O
r O
= O
0.7514 O
, O
p O
less O
than O
0.0003 O
) O
. O
Simultaneous O
measurements O
of O
glucocorticoid B-protein
receptor I-protein
content O
by O
whole-cell B-DNA
assay O
revealed O
that O
glucocorticoid B-protein
receptor I-protein
content O
in O
polymorphonuclear B-cell_type
leukocytes B-cell_type
linearly O
correlated O
with O
that O
in O
the O
corresponding I-cell_line
lymphocytes I-cell_line
( O
r O
= O
0.9482 O
, O
p O
less O
than O
0.0001 O
) O
. O
There O
were O
also O
significant O
correlations O
between O
the O
maximum O
increase O
in O
polymorphonuclear B-cell_type
leukocytes B-cell_type
and O
glucocorticoid B-protein
receptor I-protein
content O
in O
polymorphonuclear B-cell_type
leukocytes B-cell_type
( O
r O
= O
0.7239 O
, O
p O
less O
than O
0.0007 O
) O
, O
and O
between O
the O
maximum O
decrease O
in O
lymphocytes I-cell_type
and O
glucocorticoid B-protein
receptor I-protein
content O
in O
lymphocytes I-cell_line
( O
r O
= O
0.7703 O
, O
p O
less O
than O
0.0002 O
) O
. O
These O
results O
suggest O
that O
individual O
differences O
are O
preserved O
both O
in O
glucocorticoid O
responsiveness O
and O
in O
glucocorticoid B-protein
receptor I-protein
content O
in O
peripheral B-cell_type
blood I-cell_type
leukocytes I-cell_type
in O
normal O
humans O
. O
Estradiol O
receptors I-protein
in O
the O
cytosol O
of O
peripheral B-cell_type
blood I-cell_type
mononuclear I-cell_type
cells I-cell_type
in O
hepatitis O
B I-DNA
virus O
carriers O
treated O
with O
interferon-alpha B-protein
. O
Estradiol O
receptors I-protein
in O
the O
cytosol O
of O
peripheral B-cell_type
blood I-cell_type
mononuclear I-cell_type
cells I-cell_type
and O
the O
effects O
of O
interferon-alpha B-protein
( O
IFN-alpha B-protein
) O
on O
estradiol O
receptors I-protein
were O
studied O
in O
asymptomatic O
hepatitis O
B I-DNA
virus I-protein
( O
HBV O
) O
carriers O
, O
patients O
with O
chronic O
hepatitis O
B I-protein
and I-cell_type
normal O
controls O
. O
The O
level O
of O
estradiol O
receptors I-protein
in O
the O
cytosol O
of O
mononuclear I-cell_type
cells I-cell_type
was O
significantly O
lower O
in O
asymptomatic O
HBV O
carriers O
and O
patients O
with O
chronic O
hepatitis O
B O
, O
compared O
to O
normal O
controls O
. O
This O
low O
level O
of O
cytosol O
estradiol O
receptors I-protein
in O
patients O
with O
chronic O
hepatitis O
B O
was O
increased O
by O
the O
administration O
of O
IFN-alpha B-protein
. O
In O
addition O
, O
when O
peripheral B-cell_type
blood I-cell_type
mononuclear I-cell_type
cells I-cell_type
from O
patients O
with O
chronic O
hepatitis O
B O
were O
incubated O
with O
IFN-alpha B-protein
in O
vitro O
, O
the O
level O
of O
cytosol O
estradiol O
receptors I-protein
also O
increased O
by O
increasing O
the O
concentration O
of O
IFN-alpha B-protein
. O
We O
previously O
reported O
that O
the O
response O
of O
mononuclear I-cell_type
cells I-cell_type
to O
estrogen O
is O
impaired O
in O
HBV O
carriers O
, O
and O
our O
present O
results O
suggested O
that O
this O
may O
be O
due O
to O
the O
low O
level O
of O
estradiol O
receptors I-protein
in O
the O
cytosol O
of O
mononuclear I-cell_type
cells I-cell_type
. O
Association O
of O
increased O
lytic O
effector O
cell O
function O
with O
high O
estrogen B-protein
receptor I-protein
levels O
in O
tumor-bearing O
patients O
with O
breast O
cancer O
. O
Tumor-bearing O
patients O
with O
breast O
cancer O
were O
assayed O
for O
their O
natural B-cell_line
killer I-cell_line
( O
NK I-cell_line
) O
cell O
activity O
and O
for O
the O
function O
of O
activated O
cytotoxic O
T-cells B-cell_type
, O
as O
assessed O
by O
lectin-dependent O
cellular O
cytotoxicity O
( O
LDCC O
) O
. O
Tumor-bearing O
patients O
with O
breast O
cancer O
had O
a O
significant O
increase O
in O
NK O
activity O
and O
in O
LDCC B-protein
, O
as O
compared O
with O
healthy O
control O
individuals O
. O
Although O
the O
enhanced O
NK O
cell O
activity O
and O
LDCC B-protein
were O
closely O
associated O
with O
high O
levels O
( O
greater O
than O
31 O
fmol/mg I-RNA
) O
of O
estrogen B-protein
receptor I-protein
( O
ER B-protein
) O
content O
in O
the O
primary O
tumor B-cell_type
, O
no O
other O
clinical O
or O
histologic O
correlation O
between O
the O
increase O
in O
either O
parameter O
of O
cytotoxic O
effector O
cell O
function O
could O
be O
found O
. O
Thus O
, O
ER B-protein
levels O
greater O
than O
31 O
fmol/mg O
might O
be O
associated O
with O
increased O
cytotoxic O
effector O
cell O
function O
in O
tumor-bearing O
patients O
with O
breast O
cancer O
. O
Properties O
of O
glucocorticoid B-protein
receptors I-protein
in O
Epstein-Barr B-cell_line
virus-transformed I-cell_line
lymphocytes I-cell_type
from O
patients O
with O
familial O
cortisol O
resistance O
. O
In O
a O
previous O
report O
of O
two O
patients O
with O
familial O
glucocorticoid O
resistance O
due O
to O
reduced O
numbers O
of O
glucocorticoid B-protein
receptors I-protein
( O
GR B-protein
) O
, O
we O
have O
shown O
decreased O
numbers O
of O
GR B-protein
in O
peripheral B-cell_type
mononuclear I-cell_type
cells I-cell_type
and O
cultured O
fibroblasts O
but O
normal O
affinity O
of O
GR B-protein
in O
both O
patients O
. O
In O
this O
study O
, O
peripheral I-cell_line
lymphocytes I-cell_type
from O
these O
patients O
, O
one O
patient O
's O
son O
and O
daughter O
, O
and I-cell_type
normal O
subjects O
were O
transformed O
with O
Epstein-Barr O
virus O
. O
Reduced O
numbers O
and I-cell_type
normal O
affinity O
of O
GR B-protein
were O
found O
in O
the O
Epstein-Barr B-cell_line
virus-transformed I-cell_line
lymphocytes I-cell_type
from O
both O
patients O
while O
the O
son O
and O
daughter O
had O
normal O
numbers O
and O
affinity O
of O
GR B-protein
. O
The O
thermal O
stability O
of O
GR B-protein
and O
thermal O
activation O
of O
cytosolic O
receptors I-protein
in O
both O
patients O
were O
found O
to O
be O
normal O
. O
Although O
the O
percentages O
of O
nuclear O
bound O
GR B-protein
were O
similar O
in O
both O
patients O
and I-cell_type
normal O
controls O
, O
the O
absolute O
amounts O
of O
nuclear O
bound O
GR B-protein
of O
the O
patients O
were O
about O
one-half O
that O
of O
normal O
controls O
. O
These O
abnormal B-cell_type
properties O
of O
GR B-protein
( O
reduced O
numbers O
of O
GR B-protein
) O
were O
preserved O
in O
the O
transformed B-cell_type
cells I-cell_line
from O
the O
patients O
. O
Octamer O
transcription B-protein
factors I-protein
1 O
and O
2 O
each O
bind O
to O
two O
different O
functional B-DNA
elements I-DNA
in O
the O
immunoglobulin O
heavy-chain B-DNA
promoter I-DNA
. O
Immunoglobulin O
heavy-chain B-DNA
genes I-DNA
contain O
two O
conserved O
sequence I-DNA
elements I-DNA
5 O
' I-DNA
to O
the O
site I-DNA
of O
transcription O
initiation O
: O
the O
octamer O
ATGCAAAT O
and O
the O
heptamer O
CTCATGA O
. O
Both O
of O
these O
elements I-DNA
are O
required O
for O
normal O
cell-specific I-DNA
promoter I-DNA
function O
. O
The O
present O
study O
demonstrates O
that O
both O
the O
ubiquitous B-protein
and O
lymphoid-cell-specific B-protein
octamer O
transcription B-protein
factors I-protein
( O
OTF-1 B-protein
and O
OTF-2 B-protein
, O
respectively O
) O
interact O
specifically O
with O
each O
of O
the O
two O
conserved O
sequence I-DNA
elements I-DNA
, O
forming O
either O
homo- B-protein
or O
heterodimeric B-protein
complexes O
. O
This O
was O
surprising O
, O
since O
the O
heptamer O
and O
octamer O
sequence I-DNA
motifs I-DNA
bear O
no O
obvious O
similarity O
to O
each O
other O
. O
Binding I-protein
of O
either O
factor O
to O
the O
octamer O
element I-DNA
occurred O
independently O
. O
However O
, O
OTF B-protein
interaction O
with O
the O
heptamer O
sequence I-DNA
appeared O
to O
require O
the O
presence O
of O
an O
intact O
octamer O
motif I-DNA
and O
occurred O
with O
a O
spacing O
of O
either O
2 I-protein
or O
14 O
base I-DNA
pairs I-DNA
between O
the O
two O
elements I-DNA
, O
suggesting O
coordinate O
binding O
resulting O
from O
protein-protein O
interactions O
. O
The O
degeneracy O
in O
sequences O
recognized O
by O
the O
OTFs B-protein
may O
be O
important O
in O
widening O
the O
range O
over O
which O
gene I-DNA
expression O
can O
be O
modulated O
and O
in O
establishing O
cell O
type I-protein
specificity O
. O
Identification O
of O
a O
novel O
lymphoid O
specific O
octamer O
binding I-protein
protein I-protein
( O
OTF-2B B-protein
) O
by O
proteolytic O
clipping O
bandshift O
assay O
( O
PCBA O
) O
. O
The O
octamer O
sequence I-DNA
ATGCAAAT O
is O
found O
in O
the O
promoters I-DNA
of O
immunoglobulin O
( O
Ig O
) O
heavy O
and O
light O
chain O
genes I-DNA
and O
in O
the O
heavy O
chain I-DNA
enhancer I-DNA
and O
is O
a O
major O
determinant O
of O
the O
cell O
type I-protein
specific O
expression O
of O
Ig O
genes I-DNA
in O
B B-cell_type
cells I-cell_type
. O
An O
apparent O
paradox O
is O
that O
the O
same O
sequence I-DNA
serves O
as O
an O
upstream B-DNA
promoter I-DNA
or I-DNA
enhancer B-DNA
element I-DNA
in O
a O
variety O
of O
housekeeping O
genes I-DNA
such O
as O
the O
histone I-protein
H2B B-protein
and O
U O
snRNA B-DNA
genes I-DNA
. O
The O
differential O
usage O
of O
this O
regulatory I-DNA
sequence I-DNA
motif I-DNA
is O
thought O
to O
be O
mediated O
by O
different O
species O
of O
octamer O
binding I-protein
proteins I-protein
. O
One O
species O
of O
100 O
kd O
, O
designated O
OTF-1 B-protein
, O
is O
present O
in O
all O
cell O
types I-cell_type
and O
may O
exert O
its O
activating O
function O
only O
when O
it O
can O
interact O
with O
additional O
adjacent O
transcription B-protein
factors I-protein
. O
The O
lymphoid B-cell_line
cell O
specific O
octamer O
binding I-protein
protein I-protein
of O
60 O
kd O
( O
OTF-2A B-protein
) O
specifically O
stimulates O
Ig O
promoters I-DNA
which O
consist O
essentially O
of O
a O
TATA-box I-cell_line
and O
an O
octamer O
sequence I-DNA
upstream O
of O
it O
. O
Here O
we O
present O
evidence O
for O
yet O
another O
B I-cell_line
cell O
specific O
octamer O
binding I-protein
protein I-protein
of O
75 O
kd O
( O
OTF-2B B-protein
) O
. O
From O
several O
findings O
, O
including O
the O
absence O
of O
OTF-2B B-protein
( O
but O
not O
OTF-2A B-DNA
) O
from O
a O
lymphocyte I-cell_line
line O
that O
can O
not O
respond O
to O
the O
IgH B-DNA
enhancer I-DNA
, O
we O
propose O
a O
role O
of O
the O
novel O
octamer O
factor I-protein
in O
the O
long O
range O
activation O
by O
the O
IgH B-DNA
enhancer I-DNA
. O
We O
have O
used O
the O
proteolytic O
clipping O
bandshift O
assay O
( O
PCBA O
) O
technique O
to O
distinguish O
the O
three O
different O
forms O
found O
in O
B B-cell_type
cells I-cell_type
. O
This O
analysis O
indicates O
that O
the O
75 O
kd-species O
OTF-2B B-DNA
is O
closely O
related O
to O
the O
60 O
kd O
species O
OTF-2A B-DNA
. O
Inhibition O
of O
interleukin B-protein
2 I-protein
-induced O
proliferation O
of O
cloned O
murine I-cell_line
T B-cell_type
cells I-cell_type
by O
glucocorticoids O
. O
Possible O
involvement O
of O
an O
inhibitory I-protein
protein I-protein
. O
The O
ability O
of O
glucocorticoids O
to O
inhibit O
interleukin B-protein
2 I-protein
( O
IL I-protein
2 I-protein
) O
-induced O
T O
cell O
proliferation O
in O
two O
cytotoxic O
T O
cell I-protein
( O
CTL O
) I-cell_line
clones I-cell_line
has O
been O
studied O
. O
A O
complete O
inhibition O
of O
DNA B-protein
synthesis O
by O
dexamethasone O
( O
Dx O
) O
could O
be O
observed O
when O
IL I-protein
2-depleted O
cultures I-cell_line
of O
CTL B-protein
were O
either O
incubated O
for O
6 O
h O
with O
the O
hormone I-protein
prior O
to O
the O
addition O
of O
IL I-protein
2 I-protein
or O
treated O
simultaneously O
with O
Dx O
and O
a O
low O
concentration O
of O
IL I-protein
2 I-protein
. O
No O
significant O
reduction O
in O
the O
number O
and O
affinity O
of O
IL I-protein
2 I-protein
receptors I-protein
was O
seen O
after O
6 O
h O
incubation O
with O
Dx O
. O
The O
order O
of O
potency O
observed O
with O
the O
different O
steroids O
indicated O
that O
this O
inhibitory O
effect O
was O
mediated O
through O
binding O
to O
a O
specific B-protein
glucocorticoid B-protein
receptor I-protein
. O
The O
action O
of O
these O
hormones O
possibly O
involves O
the O
synthesis O
of O
an O
inhibitory I-protein
protein I-protein
( O
s O
) O
, O
since O
the O
presence O
of O
cycloheximide O
during O
the O
incubation O
with O
Dx O
prevented O
the O
inhibition O
of O
DNA B-protein
synthesis O
. O
Furthermore O
, O
supernatant O
from O
Dx-treated O
CTL O
contained O
a O
nondialyzable I-protein
factor I-protein
which O
inhibited O
DNA O
synthesis O
and O
cell O
growth O
of O
CTL I-cell_line
clones I-cell_line
induced O
by O
IL I-protein
2 I-protein
. O
Blocking O
of O
IL I-protein
2 I-protein
synthesis O
and O
IL I-protein
2 I-DNA
receptor I-protein
formation O
have O
been O
proposed O
as O
one O
of O
the O
major O
mechanisms O
of O
glucocorticoid-induced B-protein
immunosuppression O
. O
Our O
results O
indicate O
that O
these O
hormones O
may O
also O
affect O
T O
cell O
proliferation O
by O
inhibiting O
IL I-protein
2 I-protein
activity O
. O
Identification O
and O
purification O
of O
a O
human O
immunoglobulin-enhancer-binding I-protein
protein I-protein
( O
NF-kappa B-protein
B I-protein
) O
that O
activates O
transcription O
from O
a O
human O
immunodeficiency O
virus O
type O
1 I-protein
promoter O
in O
vitro O
. O
The O
enhancer-binding B-protein
factor O
NF-kappa B-protein
B I-protein
, O
which O
is O
found O
only O
in O
cells I-cell_line
that O
transcribe O
immunoglobulin O
light O
chain O
genes I-DNA
, O
has O
been O
purified O
from O
nuclear O
extracts O
of O
Namalwa B-cell_type
cells I-cell_line
( O
human B-cell_type
Burkitt I-cell_line
lymphoma I-cell_line
cells I-cell_type
) O
by O
sequence-specific O
DNA O
affinity O
chromatography O
. O
The O
purified O
NF-kappa B-protein
B I-protein
has O
been O
identified O
as O
a O
51-kDa O
polypeptide O
by O
UV-crosslinking B-protein
analysis O
. O
`` O
Footprint O
'' O
and O
methylation-interference O
analyses O
have O
shown O
that O
purified O
NF-kappa B-protein
B I-protein
has O
a O
binding O
activity O
specific O
for O
the O
kappa O
light O
chain I-DNA
enhancer I-DNA
sequence I-DNA
. O
The O
purified I-cell_line
factor I-protein
activated I-protein
in O
vitro O
transcription O
of O
the O
human O
immunodeficiency O
virus O
type O
I B-DNA
promoter I-DNA
by O
binding O
to O
an O
upstream B-DNA
NF-kappa B-protein
B-binding I-protein
site I-DNA
Lymphocyte O
glucocorticoid B-protein
receptor I-protein
binding O
in O
depression O
: O
normal O
values O
following O
recovery O
. O
The O
number O
of O
glucocorticoid B-protein
receptor I-DNA
sites I-DNA
in O
lymphocytes I-cell_type
and O
plasma O
cortisol O
concentrations O
were O
measured O
in O
20 O
patients O
who O
had O
recovered O
from O
major O
depressive O
disorder O
and O
20 O
healthy O
control O
subjects O
. O
The O
number O
of O
glucocorticoid B-protein
receptor I-DNA
sites I-DNA
in O
lymphocytes I-cell_type
from O
the O
recovered O
depressed O
group O
was O
not O
significantly O
different O
from O
that O
of O
the O
control O
group O
. O
Although O
the O
mean O
plasma O
cortisol O
concentration O
in O
recovered O
depressives O
was O
higher O
than O
in O
control O
subjects O
, O
the O
difference O
only O
just O
reached O
significance O
. O
This O
study O
shows O
that O
the O
reduction O
in O
glucocorticoid B-protein
receptor I-protein
numbers O
which O
occurs O
during O
acute O
depressive O
illness O
does O
not O
persist O
on O
recovery O
and O
is O
, O
therefore O
, O
state-dependent O
. O
Identification O
and O
purification O
of O
a O
human O
lymphoid-specific O
octamer-binding I-protein
protein I-protein
( O
OTF-2 B-protein
) O
that O
activates O
transcription O
of O
an O
immunoglobulin I-protein
promoter O
in O
vitro O
. O
The O
octamer O
sequence I-DNA
5'-ATGCAAAT O
, O
in O
either O
orientation O
, O
serves O
as O
an O
upstream B-DNA
element I-DNA
in O
a O
variety O
of O
promoters B-DNA
and O
also O
occurs O
as O
a O
modular I-DNA
enhancer B-DNA
element I-DNA
. O
It O
is O
of O
particular O
interest O
in O
immunoglobulin O
genes O
since O
it O
is O
found O
in O
the O
upstream B-DNA
regions O
of O
all O
heavy O
and O
light O
chain B-DNA
promoters B-DNA
and O
in O
the O
heavy O
chain I-DNA
enhancer I-DNA
, O
both O
of O
which O
are O
known O
to O
be O
necessary O
for O
cell-specific O
expression O
. O
We O
report O
here O
the O
chromatographic O
separation O
of O
ubiquitous B-protein
and O
B O
cell-specific O
octamer-binding B-protein
proteins I-protein
. O
The O
B I-cell_line
cell I-protein
factor I-protein
was O
purified O
to O
homogeneity O
using O
affinity O
chromatography O
and O
consists O
of O
three O
peptides O
of O
62 O
, O
61 O
, O
and O
58.5 O
+/- O
1.5 O
kd O
. O
Each O
of O
the O
polypeptides O
was O
renatured O
after O
SDS-PAGE O
and O
shown O
to O
bind O
to O
the O
octamer O
sequence I-DNA
. O
The O
specific O
DNA O
binding O
activity O
of O
the O
pure B-protein
B O
cell-specific I-protein
factor I-protein
was O
indistinguishable O
from O
that O
of O
the O
affinity-purified O
ubiquitous B-protein
factor I-protein
. O
This O
B O
cell-specific O
octamer-binding B-protein
factor I-protein
, O
in O
pure B-protein
form O
, I-protein
activated I-protein
transcription I-protein
from O
a O
kappa O
light O
chain O
promoter I-DNA
in O
vitro O
, O
thus O
demonstrating O
that O
it O
is O
indeed O
a O
B O
cell-specific I-protein
transcription I-protein
factor I-protein
for O
this O
gene I-DNA
. O
In O
addition O
to O
the O
ubiquitous B-protein
and O
B O
cell-specific O
octamer-binding B-protein
factors I-protein
, O
we O
identified O
several O
additional B-protein
proteins I-protein
, O
one O
of O
which O
is O
B I-cell_line
cell O
-specific I-cell_line
, O
that O
interact O
with O
the O
kappa B-DNA
promoter O
. O
Decreased O
deoxyribonucleic O
acid O
binding O
of O
glucocorticoid-receptor B-protein
complex I-protein
in O
cultured O
skin O
fibroblasts O
from O
a O
patient O
with O
the O
glucocorticoid O
resistance O
syndrome O
. O
A O
patient O
with O
the O
syndrome O
of O
glucocorticoid B-protein
resistance O
was O
studied O
. O
A O
27-yr-old B-cell_line
woman O
initially O
was O
diagnosed O
as O
having O
Cushing O
's O
disease O
, O
based O
on O
the O
findings O
of O
high O
plasma O
ACTH B-protein
and O
serum O
cortisol O
levels O
, O
increased O
urinary O
cortisol O
secretion O
, O
resistance O
to O
adrenal O
suppression O
with O
dexamethasone O
, O
and O
bilateral O
adrenal O
hyperplasia O
by O
computed O
tomography O
and O
scintigraphy O
of O
the O
adrenal O
glands O
. O
However O
, O
she O
had O
no O
signs O
or O
symptoms O
of O
Cushing O
's O
syndrome O
. O
During O
a O
5-yr B-DNA
follow-up O
, O
no O
clinical O
abnormalities O
developed O
, O
although O
hypercortisolism O
persisted O
. O
End-organ O
resistance O
to O
cortisol O
was O
suspected O
. O
To O
explain O
the O
end-organ O
resistance O
to O
cortisol O
, O
the O
glucocorticoid B-protein
receptors I-protein
( O
GR B-protein
) O
in O
peripheral B-cell_type
mononuclear I-cell_type
leukocytes I-cell_type
and O
cultured O
skin O
fibroblasts O
from O
a O
forearm O
skin O
biopsy O
were O
characterized O
and O
compared O
with O
the O
results O
of O
similar O
studies O
in O
normal O
subjects O
. O
The O
patient O
's O
GR B-protein
in O
whole O
cell O
assays O
had O
an O
increased O
dissociation O
constant O
( O
Kd O
) O
. O
In O
the O
cytosol O
of O
cultured O
skin O
fibroblasts O
from O
the O
patient O
, O
there O
was O
also O
decreased O
binding O
capacity O
. O
The O
thermal O
stability O
and O
the O
sedimentation O
coefficient O
in O
a O
sucrose O
density O
gradient O
of O
the O
receptors I-protein
in O
the O
cytosol O
of O
cultured O
skin O
fibroblasts O
from O
the O
patient O
and I-cell_type
normal O
subjects O
were O
similar O
. O
GR B-protein
complex O
activation O
, O
analyzed O
by O
DEAE-cellulose B-protein
chromatography O
, O
was O
decreased O
in O
the O
patient O
. O
DNA O
binding O
of O
the O
GR B-protein
complex O
after O
temperature-induced O
activation O
was O
lower O
in O
the O
patient O
than O
in O
normal O
subjects O
. O
Nuclear O
translocation O
of O
GR B-protein
complexes O
from O
the O
patient O
was O
also O
slightly O
decreased O
. O
These O
results O
suggest O
that O
the O
patient O
's O
glucocorticoid O
resistance O
was O
due O
to O
a O
decrease O
in O
the O
affinity O
of O
the O
receptor I-protein
for O
glucocorticoids O
and O
a O
decrease O
in O
the O
binding O
of O
the O
GR B-protein
complex O
to O
DNA O
. O
Granulocyte-macrophage B-protein
colony-stimulating I-protein
factor I-protein
. O
Sensitive O
and O
receptor-mediated O
regulation O
by O
1 I-protein
, O
25-dihydroxyvitamin O
D3 O
in O
normal B-cell_type
human B-cell_type
peripheral I-cell_type
blood I-cell_type
lymphocytes I-cell_type
. O
We O
show O
that O
1 I-protein
, O
25-dihydroxyvitamin O
D3 O
( O
1 O
, O
25 O
[ O
OH O
] O
2D3 I-cell_line
) O
, O
the O
most O
hormonally O
active O
metabolite O
of O
vitamin O
D3 O
, O
modulates O
sensitively O
and O
specifically O
both O
the O
protein I-protein
and O
messenger O
RNA I-RNA
accumulation O
of O
the O
multilineage O
growth I-protein
factor I-protein
granulocyte-macrophage B-protein
colony-stimulating I-protein
factor I-protein
( O
GM-CSF B-protein
) O
. O
The O
regulation O
of O
GM-CSF B-protein
expression O
is O
seen O
in O
both O
normal B-cell_type
human I-cell_type
mitogen-activated O
T B-cell_type
lymphocytes I-cell_type
and O
T B-cell_type
lymphocytes I-cell_type
from O
a O
line O
( O
S-LB1 I-cell_line
) O
transformed O
with O
human B-cell_type
T I-cell_line
cell O
lymphotropic O
virus O
1 O
( O
HTLV-1 O
) O
. O
In O
contrast O
, I-cell_line
cells I-cell_type
from O
a O
HTLV-1 B-protein
transformed B-cell_type
T O
lymphocyte I-cell_line
line O
( O
Ab-VDR B-protein
) O
established O
from O
a O
patient O
with O
vitamin O
